Reversal of multi-drug resistance by pSUPER-shRNA-mdr1 in vivo and in vitro

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 4

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

215

HTML

2404

Figures (1-9)

Tables (1-2)

Sum=2621

Jan 28, 2009 (publication date) through Feb 11, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Original Articles

World J Gastroenterol. Jan 28, 2009; 15(4): 431-440
Published online Jan 28, 2009. doi: 10.3748/wjg.15.431

Table 1 Effect of stable expression of MDR1 targeting shRNA on MDR1 mRNA, P-gp and resistance to cytotoxic drugs in HepG2/mdr1 cells

The unit of IC₅₀ was &mgr;g/mL.

^aP < 0.05;

^bP < 0.01 vs HepG2/m.

Table 2 Effect of expression of MDR1 targeting shRNA on P-gp expression, tumor growth and adiramycin sensitivity in vivo

Group	Mean growth time (d)	Mean volume (mm³)pretreatment	P-gp expression	ΔVolume (mm³) pre- & post-chemotherapy	Growth rate of tumor
HepG2	13.12 ± 1.35	66.41 ± 1.58	-	530.58 ± 23.12	8.46 ± 0.63
HepG2/m	12.65 ± 2.31	64.23 ± 2.15	97.90^b	1659.70 ± 152.54^b	23.12 ± 5.32^b
HepG2/m-sh	-	-	15.75	700.14 ± 25.61	10.39 ± 1.54

^bP < 0.01 vs HepG2/m-sh.

Citation: Pan GD, Yang JQ, Yan LN, Chu GP, Liu Q, Xiao Y, Yuan L. Reversal of multi-drug resistance by pSUPER-shRNA-mdr1 in vivo and in vitro. World J Gastroenterol 2009; 15(4): 431-440
URL: https://www.wjgnet.com/1007-9327/full/v15/i4/431.htm
DOI: https://dx.doi.org/10.3748/wjg.15.431